Six Questions For Sun Pharma MD Shanghvi
Executive Summary
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
You may also be interested in...
Six Glocal Trends That Could Lift Or Drift India Pharma In 2021
Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.
2021 Deal Action In India: Watch Private Equity And E-Pharmacy
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
AAM Launches Further Broadside At Proposed Blocking Act
A proposed US House bill that would prevent the first generic filer to challenge patents listed against the reference brand from ‘parking’ their 180-day market exclusivity has once again come under fire from the AAM.